Last reviewed · How we verify

SCT510A — Competitive Intelligence Brief

SCT510A (SCT510A) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Natural killer cell therapy. Area: Oncology.

phase 3 Natural killer cell therapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SCT510A (SCT510A) — Sinocelltech Ltd.. SCT510A is a genetically modified allogeneic natural killer cell therapy designed to enhance anti-tumor immunity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SCT510A TARGET SCT510A Sinocelltech Ltd. phase 3 Natural killer cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Natural killer cell therapy class)

  1. Sinocelltech Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SCT510A — Competitive Intelligence Brief. https://druglandscape.com/ci/sct510a. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: